Published in JAMA on July 10, 1996
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol (2000) 3.83
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
Viral dynamics of acute HIV-1 infection. J Exp Med (1999) 3.45
Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol (1999) 2.90
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol (1997) 2.59
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest (1999) 2.42
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A (2001) 1.89
Validation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples. J Clin Microbiol (2002) 1.82
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol (1997) 1.71
p24 Antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection. J Clin Microbiol (2003) 1.64
Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis (2012) 1.61
Delays in protease inhibitor use in clinical practice. J Gen Intern Med (1999) 1.54
Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replication. J Virol (2000) 1.47
High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol (2002) 1.37
Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J Virol (2002) 1.28
Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection. J Acquir Immune Defic Syndr (2009) 1.27
Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. J Virol (2004) 1.25
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis (2004) 1.18
Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol (2007) 1.16
Principles of quantitation of viral loads using nucleic acid sequence-based amplification in combination with homogeneous detection using molecular beacons. Nucleic Acids Res (2002) 1.14
Precise determination of time to reach viral load set point after acute HIV-1 infection. J Acquir Immune Defic Syndr (2012) 1.05
The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog (2014) 0.97
Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. J Immunol Methods (2014) 0.97
Can we predict the prognosis of HIV infection? How to use the findings of a prospective study. Sex Transm Infect (1998) 0.92
A simple relationship between viral load and survival time in HIV-1 infection. Proc Natl Acad Sci U S A (1999) 0.92
Maternal SDF1 3'A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission. J Virol (2000) 0.92
Engagement in HIV care among Kenyan adults and adolescents: results from a national population-based survey. J Acquir Immune Defic Syndr (2014) 0.89
Combination of immune and viral factors distinguishes low-risk versus high-risk HIV-1 disease progression in HLA-B*5701 subjects. J Virol (2012) 0.85
Early levels of CD4, neopterin, and beta 2-microglobulin indicate future disease progression. J Clin Immunol (1997) 0.84
Effect of human immunodeficiency virus infection on plasma bactericidal activity against Salmonella enterica serovar Typhimurium. Clin Vaccine Immunol (2014) 0.83
Viral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia. J Virol (1998) 0.82
Rheonix CARD(®) Technology: An Innovative and Fully Automated Molecular Diagnostic Device. Point Care (2012) 0.82
Impact of age on markers of HIV-1 disease. Future Virol (2013) 0.82
The potential role of biomarkers in HIV preventive vaccine trials. J Acquir Immune Defic Syndr (2009) 0.81
Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats. J Virol (1999) 0.80
Risk factors associated with low CD4+ lymphocyte count among HIV-positive pregnant women in Nigeria. Int J Gynaecol Obstet (2009) 0.79
Evidence of HIV exposure and transient seroreactivity in archived HIV-negative severe hemophiliac sera. Virol J (2005) 0.79
The clinical utility of viral load monitoring in HIV infection: strengths and limitations. Genitourin Med (1996) 0.79
Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers. J Virol (2015) 0.77
A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns. BMC Syst Biol (2013) 0.77
The recombinant maize ribosome-inactivating protein transiently reduces viral load in SHIV89.6 infected Chinese Rhesus Macaques. Toxins (Basel) (2015) 0.77
Recent advances. General medicine. BMJ (1998) 0.75
Dose of non-heat-treated factor VIII concentrate and HIV-1 RNA levels. JAMA (1997) 0.75
Antiretroviral therapy for human immunodeficiency virus infection in 1997. West J Med (1997) 0.75
Impact of the COBAS AmpliPrep/COBAS AMPLICOR HIV-1 MONITOR Test, Version 1.5, on clinical laboratory operations. J Clin Microbiol (2007) 0.75
Analytical characteristics and comparative evaluation of Aptima HIV-1 Quant Dx assay with Ampliprep/COBAS TaqMan HIV-1 test v2.0. Virol J (2016) 0.75
Comparison of two measures of human immunodeficiency virus (HIV) type 1 load in HIV risk groups. J Clin Microbiol (1998) 0.75
Dynamics of hybrid switching DS-I-A epidemic model. Sci Rep (2017) 0.75
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood (1996) 7.31
Association of cancer with AIDS-related immunosuppression in adults. JAMA (2001) 6.80
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet (1967) 5.38
Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med (1994) 5.32
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med (1999) 5.09
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98
Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med (2000) 4.84
Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet (1984) 4.68
Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, transmission, and disease outcome. Br Med J (Clin Res Ed) (1984) 4.39
Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA (1985) 4.26
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04
Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst (2000) 3.77
Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis (1981) 3.76
Adult T-cell lymphoma-leukaemia in Blacks from the West Indies. Lancet (1982) 3.67
The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest (1968) 3.66
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol (1990) 3.35
Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. Science (1986) 3.31
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost (2001) 3.13
Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA (1986) 3.05
Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet (1993) 3.03
Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis (2001) 2.95
Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood (1991) 2.92
Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet (1995) 2.74
The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. Int J Cancer (1982) 2.71
Mapping the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human Coxsackievirus and rhinovirus. J Biol Chem (1993) 2.70
Natural history of HIV-1 cell-free viremia. JAMA (1995) 2.58
Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA (1998) 2.55
Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation (1995) 2.54
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. Euro Surveill (2011) 2.42
Liquid nitrogen preservation of red blood cells for transfusion; a low glycerol-rapid freeze procedure. Cryobiology (1969) 2.41
Foot-and-mouth disease virus leader proteinase: purification of the Lb form and determination of its cleavage site on eIF-4 gamma. J Virol (1994) 2.41
Genetic polymorphism in CX3CR1 and risk of HIV disease. Science (2000) 2.38
Therapy may explain recent deficits in AIDS incidence. J Acquir Immune Defic Syndr (1990) 2.35
Epidemiology of human T-cell leukemia/lymphoma virus. J Infect Dis (1983) 2.26
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A (2000) 2.24
Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. Ann Intern Med (1987) 2.24
Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer (1989) 2.24
A quantification of human cells using an ERV-3 real time PCR assay. J Virol Methods (2001) 2.20
Prevalence of HIV infection in the United States, 1984 to 1992. JAMA (1996) 2.15
Preoperative history and coagulation screening in children undergoing tonsillectomy. Pediatrics (1992) 2.12
Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet (1989) 2.12
Therapy of congenital folate malabsorption. J Pediatr (1981) 2.11
Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study. Ann Intern Med (1986) 2.06
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med (1990) 2.05
Expression of alternatively spliced human T-lymphotropic virus type I pX mRNA in infected cell lines and in primary uncultured cells from patients with adult T-cell leukemia/lymphoma and healthy carriers. Proc Natl Acad Sci U S A (1992) 2.05
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
Public perceptions in relation to intention to receive pandemic influenza vaccination in a random population sample: evidence from a cross-sectional telephone survey. Euro Surveill (2009) 1.98
Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis (1982) 1.98
Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science (1988) 1.97
Mortality among chemical workers exposed to benzene and other agents. Environ Res (1983) 1.94
Nosocomial anemia. JAMA (1973) 1.93
Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci U S A (1990) 1.93
Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med (1991) 1.91
Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst (1991) 1.91
Clinical, pathologic, and immunologic features of human T-lymphotrophic virus type I-associated infective dermatitis in children. Arch Dermatol (1998) 1.90
Direct interaction of CASK/LIN-2 and syndecan heparan sulfate proteoglycan and their overlapping distribution in neuronal synapses. J Cell Biol (1998) 1.90
Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer (1997) 1.82
Evidence for heterosexual transmission and clinical manifestations of human immunodeficiency virus infection and related conditions in Lusaka, Zambia. Lancet (1986) 1.80
Risk of cancer in children with AIDS. AIDS-Cancer Match Registry Study Group. JAMA (2000) 1.79
Left-to-right atrial shunting after percutaneous mitral valvuloplasty. Incidence and long-term hemodynamic follow-up. Circulation (1990) 1.77
Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol (1993) 1.76
Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation (1993) 1.74
Crystal structure of the hCASK PDZ domain reveals the structural basis of class II PDZ domain target recognition. Nat Struct Biol (1998) 1.74
Elimination of a cirsoid aneurysm of the scalp by direct percutaneous embolization with thrombogenic coils. Case report. J Neurosurg (1990) 1.70
Human T-cell leukaemia/lymphoma virus-associated lymphoreticular neoplasia in Jamaica. Lancet (1983) 1.69
HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis. J Immunol (1987) 1.69
Incremental doses of dobutamine induce a biphasic response in dysfunctional left ventricular regions subtending coronary stenoses. Circulation (1995) 1.68
Familial testicular cancer and urogenital developmental anomalies. Cancer (1985) 1.64
Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr (1993) 1.63
What is safe sex? Suggested standards linked to testing for human immunodeficiency virus. N Engl J Med (1987) 1.63
HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens. J Immunol (1988) 1.63
Population-based monitoring of an urban HIV/AIDS epidemic. Magnitude and trends in the District of Columbia. JAMA (1992) 1.62